New advances in the development of a vaccine against paracoccidioidomycosis

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorTRAVASSOS, Luiz R.
dc.contributor.authorTABORDA, C. P.
dc.date.accessioned2014-09-30T15:17:59Z
dc.date.available2014-09-30T15:17:59Z
dc.date.issued2012
dc.description.abstractParacoccidioidomycosis (PCM) is an endemic Latin American mycosis caused by Paracoccidioides brasiliensis and also by the recently described P. lutzii. The systemic mycosis is the 10th leading cause of death due to infectious diseases in Brazil. As published, 1,853 patients died of PCM in the 1996-2006 decade in this country. The main diagnostic antigen of P brasiliensis is the 43 kDa glycoprotein gp43, and its 15-mer peptide QTLI-AIHTLAIRYAN, known as P10, contains the T-CD4(+) epitope that elicits an IFN-gamma-mediated Th1 immune response, which effectively treats mice intratracheally infected with PCM. The association of peptide P10 with antifungal drugs rendered an additive protective effect, even in immunosuppressed animals, being the basis of a recommended treatment protocol. Other immunotherapeutic tools include a peptide carrying a B cell epitope as well as protective anti-gp43 monoclonal antibodies. New delivery systems and gene therapy have been studied in prophylactic and therapeutic protocols to improve the efficacy of the recognized antigens aiming at a future vaccine as co-adjuvant therapy in patients with PCM.
dc.description.indexPubMed
dc.identifier.citationFRONTIERS IN MICROBIOLOGY, v.3, article ID 212, 6p, 2012
dc.identifier.doi10.3389/fmicb.2012.00212
dc.identifier.issn1664-302X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/7962
dc.language.isoeng
dc.publisherFRONTIERS RESEARCH FOUNDATION
dc.relation.ispartofFrontiers in Microbiology
dc.rightsopenAccess
dc.rights.holderCopyright FRONTIERS RESEARCH FOUNDATION
dc.subjectP. brasiliensis
dc.subjectP. lutzii
dc.subjectparacoccidioidomycosis
dc.subjectvaccine
dc.subjectimmunotherapy
dc.subject.wosMicrobiology
dc.titleNew advances in the development of a vaccine against paracoccidioidomycosis
dc.typearticle
dc.type.categoryreview
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalTRAVASSOS, Luiz R.:Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, BR-04032020 Sao Paulo, Brazil
hcfmusp.citation.scopus36
hcfmusp.contributor.author-fmusphcCARLOS PELLESCHI TABORDA
hcfmusp.description.articlenumber212
hcfmusp.description.volume3
hcfmusp.origemWOS
hcfmusp.origem.pubmed22701452
hcfmusp.origem.scopus2-s2.0-84868278503
hcfmusp.origem.wosWOS:000208863600262
hcfmusp.publisher.cityLAUSANNE
hcfmusp.publisher.countrySWITZERLAND
hcfmusp.relation.referenceAmaral AC, 2010, BRIT J PHARMACOL, V159, P1126, DOI 10.1111/j.1476-5381.2009.00617.x
hcfmusp.relation.referenceAmorim J., 2010, THESIS U SAO PAULO S
hcfmusp.relation.referenceArruda C, 2007, MICROBES INFECT, V9, P308, DOI 10.1016/j.micinf.2006.12.005
hcfmusp.relation.referenceArruda C, 2007, MICROBES INFECT, V9, P704, DOI 10.1016/j.micinf.2007.02.014
hcfmusp.relation.referenceBatista J, 2010, MYCOSES, V53, P176, DOI 10.1111/j.1439-0507.2008.01687.x
hcfmusp.relation.referenceBraga CJM, 2009, INFECT IMMUN, V77, P1700, DOI 10.1128/IAI.01470-08
hcfmusp.relation.referenceBuissa-Filho R, 2008, INFECT IMMUN, V76, P3321, DOI 10.1128/IAI.00349-08
hcfmusp.relation.referenceCarvalho KC, 2005, MICROBES INFECT, V7, P55, DOI 10.1016/j.micinf.2004.09.008
hcfmusp.relation.referenceCisalpino PS, 1996, J BIOL CHEM, V271, P4553
hcfmusp.relation.referenceDemicheli MC, 2007, MYCOSES, V50, P397, DOI 10.1111/j.1439-0507.2007.01389.x
hcfmusp.relation.referenceDemicheli MC, 2006, MYCOSES, V49, P184, DOI 10.1111/j.1439-0507.2006.01229.x
hcfmusp.relation.referenceDiniz SN, 2004, VACCINE, V22, P485, DOI 10.1016/j.vaccine.2003.07.017
hcfmusp.relation.referenceMartins EMD, 2009, MYCOPATHOLOGIA, V168, P51, DOI 10.1007/s11046-009-9197-5
hcfmusp.relation.referenceFernandes VC, 2011, MICROBES INFECT, V13, P1062, DOI 10.1016/j.micinf.2011.06.004
hcfmusp.relation.referenceFernandes VC, 2012, MYCOPATHOLOGIA, V174, P93, DOI 10.1007/s11046-012-9530-2
hcfmusp.relation.referenceFerreira KS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015935
hcfmusp.relation.referenceFranco M, 1993, Curr Top Med Mycol, V5, P115
hcfmusp.relation.referenceGrosso DD, 2003, INFECT IMMUN, V71, P6534, DOI 10.1128/IAI.71.11.6534-6542.2003
hcfmusp.relation.referenceIwai LK, 2007, CLIN VACCINE IMMUNOL, V14, P474, DOI 10.1128/CVI.00458-06
hcfmusp.relation.referenceIwai LK, 2003, MOL MED, V9, P209
hcfmusp.relation.referenceMagalhaes A, 2012, CLIN VACCINE IMMUNOL, V19, P23, DOI 10.1128/CVI.05414-11
hcfmusp.relation.referenceMarques AF, 2006, ANTIMICROB AGENTS CH, V50, P2814, DOI 10.1128/AAC.00220-06
hcfmusp.relation.referenceMarques AF, 2008, MICROBES INFECT, V10, P1251, DOI 10.1016/j.micinf.2008.07.027
hcfmusp.relation.referenceMartins EMDN, 2007, VACCINE, V25, P7893, DOI 10.1016/j.vaccine.2007.09.011
hcfmusp.relation.referenceMatute DR, 2006, MOL BIOL EVOL, V23, P65, DOI 10.1093/molbev/msj008
hcfmusp.relation.referenceMayorga O, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00154
hcfmusp.relation.referenceMcEwen J G, 1995, Arch Med Res, V26, P305
hcfmusp.relation.referencePavanelli WR, 2007, MYCOPATHOLOGIA, V163, P117, DOI 10.1007/s11046-007-0095-4
hcfmusp.relation.referencePinto AR, 2000, VACCINE, V18, P3050, DOI 10.1016/S0264-410X(00)00074-8
hcfmusp.relation.referencePrado M, 2009, MEM I OSWALDO CRUZ, V104, P513, DOI 10.1590/S0074-02762009000300019
hcfmusp.relation.referencePUCCIA R, 1986, INFECT IMMUN, V53, P199
hcfmusp.relation.referencePUCCIA R, 1991, ARCH BIOCHEM BIOPHYS, V289, P298, DOI 10.1016/0003-9861(91)90475-X
hcfmusp.relation.referenceReis BS, 2008, VACCINE, V26, P5461, DOI 10.1016/j.vaccine.2008.07.097
hcfmusp.relation.referenceRESTREPO A, 1985, SABOURAUDIA, V23, P23
hcfmusp.relation.referenceRibeiro AM, 2009, VACCINE, V27, P606, DOI 10.1016/j.vaccine.2008.10.022
hcfmusp.relation.referenceRibeiro AM, 2010, VACCINE, V28, P1528, DOI 10.1016/j.vaccine.2009.11.062
hcfmusp.relation.referenceRittner GMG, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001519
hcfmusp.relation.referenceRODRIGUES EG, 1994, J MED VET MYCOL, V32, P77
hcfmusp.relation.referenceSaraiva ECO, 1996, J MED VET MYCOL, V34, P155
hcfmusp.relation.referenceShikanai-Yasuda M. A., 2005, EXPERT OPIN PHARMACO, V6, P385, DOI 10.1517/14656566.6.3.385
hcfmusp.relation.referenceShikanai-Yasuda MA, 2006, REV SOC BRAS MED TRO, V39, P297, DOI 10.1590/S0037-86822006000300017
hcfmusp.relation.referenceTaborda CP, 2004, SCAND J IMMUNOL, V59, P58, DOI 10.1111/j.0300-9475.2004.01359.x
hcfmusp.relation.referenceTaborda CP, 1998, INFECT IMMUN, V66, P786
hcfmusp.relation.referenceTeixeira MM, 2009, MOL PHYLOGENET EVOL, V52, P273, DOI 10.1016/j.ympev.2009.04.005
hcfmusp.relation.referenceTravassos LR, 2004, PATHOGENIC FUNGI: HOST INTERACTIONS AND EMERGING STRATEGIES FOR CONTROL, P241
hcfmusp.relation.referenceTravassos L. R., 2011, J INVASIVE FUNGAL IN, V5, P1
hcfmusp.relation.referenceTravassos LR, 2004, MYCOTA, V12, P279
hcfmusp.relation.referenceTravassos LR, 2008, MYCOPATHOLOGIA, V165, P341, DOI 10.1007/s11046-007-9056-1
hcfmusp.relation.referenceXander P, 2007, MICROBES INFECT, V9, P1484, DOI 10.1016/j.micinf.2007.08.001
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication5bfd29e1-5d6a-4174-b619-aec0a650e256
relation.isAuthorOfPublication.latestForDiscovery5bfd29e1-5d6a-4174-b619-aec0a650e256
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_TRAVASSOS_New_advances_in_the_development_of_a_vaccine_2012.PDF
Tamanho:
1.18 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - LIM/53